DESCRIPTON: (provided by application) Pancreatic ductal adenocarcinomas (PDACs) exhibit a plethora of molecular alterations that include mutations in the K-ras, p53, p16 and Smad4 genes, and overexpress multiple mitogenic growth factors and their tyrosine kinase receptors. PDACs also express high levels of transforming growth factor-beta (TGF-beta) isoforms, but are resistant to TGF-beta-mediated growth inhibition because they harbor Smad4 mutations, overexpress Smad6 or Smad7, and under-express the type I TGF-beta receptor (TbetaRI). The net result of these alterations is enhanced mitogenic signaling in conjunction with loss of negative growth constraints. The existence of redundant mechanisms for inducing resistance to TGF-beta-mediated growth inhibition : about together with our finding that overexpression of either TGF-beta ligands or the type II TGF-beta receptor (TbetaRII) in PDAC correlates with shortened patient survival, underscore the importance of TGF-beta-mediated events in PDAC. However, the mechanisms whereby TGF-betas may confer a growth advantage to pancreatic cancer cells are not known. In this proposal we will use subcutaneous and orthotopic nude mouse models of PDAC in order to test the hypothesis that cancer cell derived TGF-betas act in vivo to promote cancer growth via two distinct pathways. We will assess whether TGF-betas act via paracrine pathways on adjoining cellular elements by studying the effects of a soluble TbetaRII construct. We will also determine whether TGF-betas act directly on the cancer cells to enhance invasion and metastasis, using dominant-negative and full length TbetaRII constructs, and a constitutively active TbetaRI construct. Because Smad7 enhances pancreatic cancer cell tumorigenicity and blocks the growth suppressive actions of TGF-betal without attenuating its ability to promote the expression of genes implicated in cancer spread, we will assess the contribution of Smad7 overexpression to the biological aggressiveness of PDAC. To this end we will investigate the role of specific genes that are regulated by TGF-beta1 in a setting in which Smad7 is overexpressed by assessing their function in cultured pancreatic cancer cells and their expression in PDAC samples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA075059-10
Application #
7022205
Study Section
Special Emphasis Panel (ZRG1-PTHB (01))
Program Officer
Blair, Donald G
Project Start
1997-09-30
Project End
2008-02-28
Budget Start
2006-03-01
Budget End
2008-02-28
Support Year
10
Fiscal Year
2006
Total Cost
$347,417
Indirect Cost
Name
Dartmouth College
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Eibl, Guido; Cruz-Monserrate, Zobeida; Korc, Murray et al. (2018) Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet 118:555-567
Simpson, Rachel E; Yip-Schneider, Michele T; Wu, Huangbing et al. (2018) Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. Am J Surg :
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Quirin, Kayla A; Kwon, Jason J; Alioufi, Arafat et al. (2018) Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. Mol Ther Methods Clin Dev 8:8-20
Liu, Hung-Yi; Korc, Murray; Lin, Chien-Chi (2018) Biomimetic and enzyme-responsive dynamic hydrogels for studying cell-matrix interactions in pancreatic ductal adenocarcinoma. Biomaterials 160:24-36
Kota, Janaiah; Hancock, Julie; Kwon, Jason et al. (2017) Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett 391:38-49
Lai, Xianyin; Wang, Mu; McElyea, Samantha Deitz et al. (2017) A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett 393:86-93
Duell, Eric J; Lujan-Barroso, Leila; Sala, NĂºria et al. (2017) Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Int J Cancer 141:905-915
Prabhu, Lakshmi; Wei, Han; Chen, Lan et al. (2017) Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. Oncotarget 8:39963-39977
Nguyen, Hai V; Gore, Jesse; Zhong, Xin et al. (2016) MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection. J Gastrointest Surg 20:1699-706

Showing the most recent 10 out of 88 publications